Jay Mohr serves as General Partner of NYBC Ventures. Jay is an accomplished entrepreneur and life science transaction specialist with more than three decades of experience in biopharma. He also serves as Executive Vice President at New York Blood Center, where he also oversees Comprehensive Cell Solutions, a CDMO focusing on cellular therapy development and manufacturing.
Jay has held the position of CEO for two venture-capital-backed companies, Gloucester Pharmaceuticals and Variagenics, Inc., that both resulted in successful exits for shareholders. He was founding CEO of Gloucester, a hematology therapeutics company acquired by Celgene. Subsequent to Gloucester, Jay co-founded Locust Walk Partners, a global transaction advisory firm for the life sciences.
Jay currently serves as the Chairman of the Board of the T1D Exchange and is a Director on the Boards of Mesentech and the Maine Technological Institute. He holds an MBA from The Wharton School of the University of Pennsylvania and a BA in economics and German from Vanderbilt University.